Individual residual symptoms and functional impairment in patients with depression

Psychiatry Research

Volumn 220, Issue 1-2, 2014, Pages 258-262

  Romera, Irene ^a,b   Pérez, Víctor ^c   Quail, Deborah ^d   Berggren, Lovisa ^e   Lenox Smith, Alan ^d   Gilaberte, Inmaculada ^f  

^a Department of Clinical Research Lilly ^*  (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Functioning; Major depression disorder; Residual symptoms

Indexed keywords

DULOXETINE; ANTIDEPRESSANT AGENT; THIOPHENE DERIVATIVE;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPLORATORY RESEARCH; FEMALE; FUNCTIONAL DISEASE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; OPEN STUDY; PAIN; PHYSICAL DISEASE; POST HOC ANALYSIS; REMISSION; RESIDUAL SYMPTOM; RISK REDUCTION; SLEEP DISORDER; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PSYCHOLOGY; SLEEP DISORDERS;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; SLEEP DISORDERS; THIOPHENES;

EID: 84908245385     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.07.042     Document Type: Article

References (32)

1. American Psychiatric Association Diagnostic and Statistic Manual of Mental Disorders (DSM-IV-TRed.) 2000, American Psychiatric Association, Washington, DC.
2. Collins S.L., Moore R.A., McQuay H.J. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997, 72:95-97.
3. Dombrovski A.Y., Mulsant B.H., Houck P.R., Mazumdar S., Lenze E.J., Andreescu C., Cyranowski J.M., Reynolds C.F. Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of Affective Disorders 2007, 103:77-82.
4. Dombrovski A.Y., Cyranowski J.M., Mulsant B.H., Houck P.R., Buysse D.J., Andreescu C., Thase M.E., Mallinger A.G., Frank E. Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?. Depression and Anxiety 2008, 25:1060-1066.
5. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, (Revised), National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD.
6. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960, 23:56-62.
7. Iovieno N., van Nieuwenhuizen A., Clain A., Baer L., Nierenberg A.A. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depression and Anxiety 2011, 28:137-144.
8. Kennedy N., Foy K., Sherazi R., McDonough M., McKeon P. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disorders 2007, 9:25-37.
9. Leon A.C., Olfson M., Portera L., Farber L., Sheehan D.V. Assessing psychiatric impairment in primary care with the Sheehan disability scale. International Journal of Psychiatry in Medicine 1997, 27:93-105.
10. McClintock S.M., Husain M.M., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Trivedi M.H., Cook I., Morris D., Warden D., Rush A.J. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. Journal of Clinical Psychopharmacology 2011, 31:180-186.
11. Miller I.W., Keitner G.I., Schatzberg A.F., Klein D.N., Thase M.E., Rush A.J., Marckovitz J.C., Schlarger D.S., Kornstein S., Davis S.M., Harrison W.M., Keller M.B. The treatment of chronic depression, part 3: psychological functioning before and after treatment with sertraline or imipramine. Journal of Clinical Psychiatry 1998, 59:608-619.
12. Nierenberg A.A., Husain M.M., Trivedi M.H., Fava M., Warden D., Wisniewski S.R., Miyahara S., Rush A.J. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychological Medicine 2009, 40:41-50.
13. Ormel J., Oldehinkel A.J., Nolen W.A., Vollebergh W. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Archives of General Psychiatry 2004, 61:387-392.
14. Papakostas G.I. Major depressive disorder: psychosocial impairment and key considerations in functional improvement. American Journal of Managed Care 2009, 15:S316-S321.
15. Perahia D.G., Gilaberte I., Wang F., Wiltse C.G., Huckins S.A., Clemens J.W., Montgomery S.A., Montejo A.L., Detke M.J. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. British Journal of Psychiatry 2006, 188:346-353.
16. Perahia D.G., Maina G., Thase M.E., Spann M.E., Wang F., Walker D.J., Detke M.J. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2009, 70:706-716.
17. Romera I., Perez V., Menchón J.M., Delgado-Cohen H., Polavieja P., Gilaberte I. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. European Psychiatry 2010, 25:58-65.
18. Romera I., Pérez V., Menchón J.M., Polavieja P., Gilaberte I. Optimal cutoff point of the hamilton rating scale for depression according to normal levels of social and occupational functioning. Psychiatry Research 2011, 186:133-137.
19. Romera I., Pérez V., Ciudad A., Caballero L., Roca M., Polavieja P., Gilaberte I. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry 2013, 13:51.
20. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):S22-S33.
21. Sheehan K.H., Sheehan D.V. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan disability scale. International Clinical Psychopharmacology 2008, 23:70-83.
22. Simon G.E., Revicki D., Heiligenstein J., Grothaus L., VonKorff M., Katon W.J., Hylan T.R. Recovery from depression, work productivity and health care costs among primary care patients. General Hospital Psychiatry 2000, 22:153-162.
23. Solomon D.A., Leon A.C., Endicott J., Mueller T.I., Coryell W., Shea M.T., Keller M.B. Psychosocial impairment and recurrence of major depression. Comprehensive Psychiatry 2004, 45:423-430.
24. Solomon D.A., Leon A.C., Coryel W., Mueller T.I., Posternak M., Endicott J., Keller M.B. Predicting recovery from episodes of major depression. Journal of Affective Disorders 2008, 107:285-291.
25. Taylor D.J., Walters H.M., Vittengl J.R., Krebaum S., Jarrett R.B. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?. Journal of Affective Disorders 2009, 123:181-187.
26. Trivedi M.H., Corey-Lisle P.K., Guo Z., Lennox R.D., Pikalov A., Kim E. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. International Clinical Psychopharmacology 2009, 24:133-138.
27. Yang H., Chuzi S., Sinicropi-Yao L., Johnson D., Chen Y., Clain A., Baer L., McGrath P.J., Stewart J.W., Fava M., Papakostas G.I. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. European Archives of Psychiatry and Clinical Neuroscience 2010, 260:145-150.
28. Zimmerman M., Posternak M.A., Chelminski I. Is the cutoff to define remission on the Hamilton rating scale for depression too high?. Journal of Nervous and Mental Disease 2005, 193:170-175.
29. Zimmerman M., McGlinchey J.B., Posternak M.A., Friedman M., Attiullah N., Boerescu D. How should remission from depression be defined? The depressed patient's perspective. American Journal of Psychiatry 2006, 163:148-150.
30. Zimmerman M., Posternak M.A., Chelminski I. Heterogeneity among depressed outpatients considered to be in remission. Comprehensive Psychiatry 2007, 48:113-117.
31. Zimmerman M., Martinez J., Attiullah N., Friedman M., Toba C., Boerescu D.A., Rahgeb M. Further evidence that the cutoff to define remission on the 17-item Hamilton depression rating scale should be lowered. Depression and Anxiety 2012, 29:159-165.
32. Zimmerman M., Martinez J.H., Attiullah N., Friedman M., Toba C., Boerescu D.A., Ragheb M. A new type of scale for determining remission from depression: the remission from depression questionnaire. Journal of Psychiatric Research 2013, 47:78-82.